公开(公告)号：US20190316100A1

公开(公告)日：2019-10-17

申请号：US16237901

申请日：2019-01-02

Applicant: CELLECTIS

Inventor： Philippe Duchateau ,  Alexandre Juillerat ,  Julien Valton ,  Claudia Bertonati ,  Jean-Charles Epinat ,  George H. Silva

IPC: C12N9/16 ,  C12P19/34 ,  C07K14/47 ,  C12N9/22

Abstract: The present invention relates to new Transcription Activator-Like Effector proteins and more particularly new Transcription Activator-Like Effector Nucleases (TALENs) that can efficiently target and process nucleic acids. The present invention also concerns methods to use these new Transcription Activator-Like Effector proteins. The present invention also relates to vectors, compositions and kits in which Transcription Activator-Like Effector proteins of the present invention are used.

公开(公告)号：US12209125B2

公开(公告)日：2025-01-28

申请号：US16755082

申请日：2018-03-09

Applicant: CELLECTIS

Inventor： Brian Busser ,  Philippe Duchateau ,  Alexandre Juillerat ,  Laurent Poirot ,  Julien Valton

IPC: A61K35/00 ,  A61K39/00 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N5/10

Abstract: The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.

公开(公告)号：US10813951B2

公开(公告)日：2020-10-27

申请号：US15037988

申请日：2014-11-21

Applicant: CELLECTIS

Inventor： Julien Valton ,  Philippe Duchateau ,  David Sourdive

IPC: A61K35/17 ,  C12N5/0783 ,  A61K45/06 ,  A61K31/7076

Abstract: The present invention relates to the use of “off-the-shelf” allogeneic therapeutic cells for immunotherapy in conjunction with chemotherapy to treat patients with cancer. In particular, the inventors develop a method of engineering allogeneic T-cell resistant to chemotherapeutic agents. The therapeutic benefits afforded by this strategy should be enhanced by the synergistic effects between chemotherapy and immunotherapy. In particular, the present invention relates to a method for modifying T-cells by inactivating at least one gene encoding T-cell receptor component and by modifying said T-cells to confer drug resistance. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer.

公开(公告)号：US11136566B2

公开(公告)日：2021-10-05

申请号：US16237901

申请日：2019-01-02

Applicant: CELLECTIS

Inventor： Philippe Duchateau ,  Alexandre Juillerat ,  Julien Valton ,  Claudia Bertonati ,  Jean-Charles Epinat ,  George H. Silva

IPC: C12N9/16 ,  C12N15/63 ,  C12N5/071 ,  C12N5/10 ,  C07K14/195 ,  C12N9/22 ,  C07K14/47 ,  A61K38/00 ,  C12P19/34

Abstract: The present invention relates to new Transcription Activator-Like Effector proteins and more particularly new Transcription Activator-Like Effector Nucleases (TALENs) that can efficiently target and process nucleic acids. The present invention also concerns methods to use these new Transcription Activator-Like Effector proteins. The present invention also relates to vectors, compositions and kits in which Transcription Activator-Like Effector proteins of the present invention are used.

公开(公告)号：US20150225465A1

公开(公告)日：2015-08-13

申请号：US14696920

申请日：2015-04-27

Applicant: Cellectis

Inventor： Claudia BERTONATI ,  Philippe Duchateau ,  Alexandre Juillerat ,  George Silva ,  Julien Valton

IPC: C07K14/195 ,  C12N15/90 ,  C12N9/22

CPC classification number: C07K14/195 ,  A01K67/0275 ,  A01K2217/07 ,  C07K2319/80 ,  C12N9/22 ,  C12N15/62 ,  C12N15/87 ,  C12N15/902 ,  C12N15/907 ,  C12Y301/21

Abstract: The present invention concerns new modular base-per-base specific nucleic acid binding domains (MBBBD) derived from newly identified proteins from the bacterial endosymbiont Burkholderia Rhizoxinica and their use for engineering nucleic acid processing enzymes, such as specific endonucleases or transcription activators.

Abstract translation: 本发明涉及从新鉴定的来自细菌内分泌杆菌伯克霍尔德杆菌（Burkholderia Rhizoxinica）的新鉴定的蛋白质中获得的新的基于碱基的碱基特异性核酸结合结构域（MBBBD）及其用于工程化核酸加工酶如特异性内切核酸酶或转录激活子的用途。

公开(公告)号：US11903968B2

公开(公告)日：2024-02-20

申请号：US16629506

申请日：2018-07-20

Applicant: CELLECTIS

Inventor： Philippe Duchateau ,  Anne-Sophie Gautron ,  Laurent Poirot ,  Julien Valton

IPC: C12N5/00 ,  A61K35/17 ,  A61K39/395 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/113

CPC classification number: A61K35/17 ,  A61K39/39541 ,  C07K16/2818 ,  C12N5/0636 ,  C12N15/113 ,  C12N2310/14 ,  C12N2510/00

Abstract: The invention pertains to the field of adoptive cell immunotherapy. It provides with engineered immune cells comprising genetic alteration into genes which are involved into immune functions downregulation, especially in response to environment signals such as nutrients depletion. Such method allows the production of more potent immune cells in the context of tumors' microenvironment.

公开(公告)号：US11873511B2

公开(公告)日：2024-01-16

申请号：US16340222

申请日：2017-10-19

Applicant: CELLECTIS

Inventor： Brian Busser ,  Philippe Duchateau ,  Alexandre Juillerat ,  Laurent Poirot ,  Julien Valton

IPC: C12N5/078 ,  A61K35/17 ,  C12N15/90 ,  C12N9/22 ,  C12N5/0783

CPC classification number: C12N5/0638 ,  A61K35/17 ,  C12N9/22 ,  C12N15/907 ,  C12N2510/00 ,  C12N2750/14143 ,  C12N2830/008

Abstract: The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.

公开(公告)号：US11198856B2

公开(公告)日：2021-12-14

申请号：US15069672

申请日：2016-03-14

Applicant: CELLECTIS

Inventor： Philippe Duchateau ,  Julien Valton ,  Claudia Bertonati ,  Jean-Charles Epinat ,  George H. Silva ,  Alexandre Juillerat ,  Marine Beurdeley

IPC: C12N9/16 ,  C12N15/63 ,  C07K14/195 ,  C12N9/22 ,  C07K14/47 ,  A61K38/00 ,  C12P19/34

Abstract: The present invention relates to a method for the generation of compact Transcription Activator-Like Effector Nucleases (TALENS) that can efficiently target and process double-stranded DNA. More specifically, the present invention concerns a method for the creation of TALENs that consist of a single TALE DNA binding domain fused to at least one catalytic domain such that the active entity is composed of a single polypeptide chain for simple and efficient vectorization and does not require dimerization to target a specific single double-stranded DNA target sequence of interest and process DNA nearby the DNA target sequence. The present invention also relates to compact TALENs, vectors, compositions and kits used to implement the method.

公开(公告)号：US11014989B2

公开(公告)日：2021-05-25

申请号：US15546633

申请日：2016-01-25

Applicant: Cellectis

Inventor： Julianne Smith ,  Julien Valton ,  Alexandre Juillerat ,  Philippe Duchateau ,  Barbra Johnson Sasu ,  Arvind Rajpal

IPC: A61K35/17 ,  C07K16/28 ,  C07K14/725 ,  C07K16/30 ,  C12N5/00 ,  C12N5/0783 ,  A61K39/00 ,  A61K39/395 ,  C07K14/705 ,  C07K14/735 ,  G01N15/10 ,  G01N15/14 ,  G01N15/00

Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward CLL1 positive cells. The engineered immune cells endowed with such CARs are particularly suited for immunotherapy for treating cancer, in particular leukemia.

公开(公告)号：US10301614B2

公开(公告)日：2019-05-28

申请号：US14387162

申请日：2013-03-15

Applicant: CELLECTIS, S.A.

Inventor： Philippe Duchateau ,  Julien Valton

IPC: C12N15/10 ,  G01N33/53 ,  C07K14/47 ,  C12N9/22

Abstract: The present invention relates to polypeptides and more particularly to Transcription Activator-Like Effector derived proteins that allow to efficiently target and/or process nucleic acids. Particularly, the present invention reports the characterization of TALE derived proteins that can efficiently target methylated DNA. The present invention more specifically relates to TALE derived proteins that allow activation of methylated promoters responsible for gene silencing.